Press Releases Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
30.37 ^CNY	-1.72%		-11.15%	-26.36%

05-10	China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy	MT
04-29	Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor	03-26	AQ
Recent Biosimilar Approvals	12-21	AQ
Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S	23-10-25	AQ
Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab	23-07-18	AQ
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar	23-06-16	BU
Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	23-04-17	AQ
Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	23-04-14	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors	23-03-13	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors	23-03-08	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors	23-03-06	BU
China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra	23-01-17	AQ
China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)	23-01-16	BU
Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-?-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium	22-12-05	AQ
Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit	22-12-05	AQ
Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit	22-12-02	BU
Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium	22-12-02	BU
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)	22-11-01	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)	22-10-14	BU
Bio-Thera Solutions Announces Details of Poster Presentation of a Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta at Vaccine Summit 2022	22-10-11	BU
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA	22-10-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

Press Releases

Filters